Monitoring relapsing remitting MS patients

被引：5

作者：

Bourdette, D ^{[1
]}

Antel, J

McFarland, H

Montgomery, E

机构：

[1] Oregon Hlth Sci Univ, Dept Neurol, Multiple Sclerosis Ctr Oregon, Portland, OR 97201 USA

[2] Dept Vet Affairs Med Ctr, Neurol Serv, Portland, OR 97201 USA

[3] Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada

[4] NIH, Neuroimmunol Branch, Bethesda, MD 20892 USA

[5] Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA

[6] Cleveland Clin Fdn, Dept Neurosci, Cleveland, OH 44195 USA

来源：

JOURNAL OF NEUROIMMUNOLOGY | 1999年 / 98卷 / 01期

关键词：

multiple sclerosis; treatment; immunomodulation; magnetic resonance imaging;

D O I：

10.1016/S0165-5728(99)00076-4

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The availability of safe and partially effective disease modifying therapies necessitates changes in how neurologists monitor patients with relapsing remitting multiple sclerosis (RRMS). Neurologists need to make the diagnosis of MS as soon as possible to be able to initiate therapy-early in the course of disease. In deciding whom to treat, neurologists should consider information on disease activity and burden acquired from the neurologic history and examination and magnetic resonance imaging (MRT). Patients not on a disease modifying therapy should undergo yearly clinical assessments and periodic cerebral MRT to monitor for changes in disease activity. Patients on disease modifying therapy should undergo regular clinical assessments. to monitor for side-effects and disease activity. Cerebral. MRT scanning may also be useful in assessing patients on therapy, particularly when considering changes in therapy. (C) 1999 Elsevier Science B.V. All rights reserved.

引用

页码：16 / 21

页数：6

共 24 条

[1] INTERFERONS AND MULTIPLE-SCLEROSIS [J].

ARNASON, BGW ;

REDER, AT .

CLINICAL NEUROPHARMACOLOGY, 1994, 17 (06) :495-547

[2] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

DUQUETTE, P ;

GIRARD, M ;

DESPAULT, L ;

DUBOIS, R ;

KNOBLER, RL ;

LUBLIN, FD ;

KELLEY, L ;

FRANCIS, GS ;

LAPIERRE, Y ;

ANTEL, J ;

FREEDMAN, M ;

HUM, S ;

GREENSTEIN, JI ;

MISHRA, B ;

MULDOON, J ;

WHITAKER, JN ;

EVANS, BK ;

LAYTON, B ;

SIBLEY, WA ;

LAGUNA, J ;

KRIKAWA, J ;

PATY, DW ;

OGER, JJ ;

KASTRUKOFF, LF ;

MOORE, GRW ;

HASHIMOTO, SA ;

MORRISON, W ;

NELSON, J ;

GOODIN, DS ;

MASSA, SM ;

GUTTERIDGE, E ;

ARNASON, BGW ;

NORONHA, A ;

REDER, AT ;

MARTIA, R ;

EBERS, GC ;

RICE, GPA ;

LESAUX, J ;

JOHNSON, KP ;

PANITCH, HS ;

BEVER, CT ;

CONWAY, K ;

WALLENBERG, JC ;

BEDELL, L ;

VANDENNOORT, S ;

WEINSHENKER, B ;

WEISS, W ;

REINGOLD, S ;

PACHNER, A ;

TAYLOR, W .

NEUROLOGY, 1993, 43 (04) :655-661

[3]

EBERS GC, 1997, MULT SCLER, P403

[4] QUANTITATIVE BRAIN MRI LESION LOAD PREDICTS THE COURSE OF CLINICALLY ISOLATED SYNDROMES SUGGESTIVE OF MULTIPLE-SCLEROSIS [J].

FILIPPI, M ;

HORSFIELD, MA ;

MORRISSEY, SP ;

MACMANUS, DG ;

RUDGE, P ;

MCDONALD, WI ;

MILLER, DH .

NEUROLOGY, 1994, 44 (04) :635-641

[5] CORRELATION OF NEUROPSYCHOLOGICAL AND MRI FINDINGS IN CHRONIC PROGRESSIVE MULTIPLE-SCLEROSIS [J].

FRANKLIN, GM ;

HEATON, RK ;

NELSON, LM ;

FILLEY, CM ;

SEIBERT, C .

NEUROLOGY, 1988, 38 (12) :1826-1829

[6]

GOODKIN DE, 1988, ARCH PHYS MED REHAB, V69, P850

[7] SERIAL GADOLINIUM-ENHANCED MAGNETIC-RESONANCE-IMAGING SCANS IN PATIENTS WITH EARLY, RELAPSING-REMITTING MULTIPLE-SCLEROSIS - IMPLICATIONS FOR CLINICAL-TRIALS AND NATURAL-HISTORY [J].

HARRIS, JO ;

FRANK, JA ;

PATRONAS, N ;

MCFARLIN, DE ;

MCFARLAND, HF .

ANNALS OF NEUROLOGY, 1991, 29 (05) :548-555

[8] Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis [J].

Jacobs, LD ;

Cookfair, DL ;

Rudick, RA ;

Herndon, RM ;

Richert, JR ;

Salazar, AM ;

Fischer, JS ;

Goodkin, DE ;

Granger, CV ;

Simon, JH ;

Alam, JJ ;

Bartoszak, DM ;

Bourdette, DN ;

Braiman, J ;

Brownscheidle, CM ;

Coats, ME ;

Cohan, SL ;

Dougherty, DS ;

Kinkel, RP ;

Mass, MK ;

Munschauer, FE ;

Priore, RL ;

Pullicino, PM ;

Scherokman, BJ ;

WeinstockGuttman, B ;

Whitman, RH ;

Baird, WC ;

Fillmore, M ;

Bona, LM ;

ColonRuiz, ME ;

Nadine, BS ;

Donovan, A ;

Bennett, S ;

Kieffer, YM ;

Umhauer, MA ;

Miller, CE ;

Kilic, AK ;

Sargent, EL ;

Schachter, M ;

Shucard, DW ;

Weider, V ;

Catalano, BA ;

Cervi, JM ;

Czekay, C ;

Farrell, JL ;

Filippini, JS ;

Matyas, RC ;

Michienzi, KE ;

Ito, M ;

OMalley, JA .

ANNALS OF NEUROLOGY, 1996, 39 (03) :285-294

[9] COPOLYMER-1 REDUCES RELAPSE RATE AND IMPROVES DISABILITY IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - RESULTS OF A PHASE-III MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

JOHNSON, KP ;

BROOKS, BR ;

COHEN, JA ;

FORD, CC ;

GOLDSTEIN, J ;

LISAK, RP ;

MYERS, LW ;

PANITCH, HS ;

ROSE, JW ;

SCHIFFER, RB ;

VOLLMER, T ;

WEINER, LP ;

WOLINSKY, JS ;

BIRD, SJ ;

CONSTANTINESCU, C ;

KOLSON, DL ;

GONZALEZSCARANO, F ;

BRENNAN, D ;

PFOHL, D ;

MANDLER, RN ;

ROSENBERG, GA ;

JEFFREY, C ;

BARGER, GR ;

GANDHI, B ;

MOORE, PM ;

ROGERS, LR ;

LISAK, D ;

SMITH, L ;

ELLISON, GW ;

BAUMHEFNER, RW ;

CRAIG, SL ;

JALBUT, SS ;

KATZ, E ;

CONWAY, KL ;

BURNS, JB ;

SHIBA, C ;

GIANG, DW ;

PETRIE, MD ;

GUARNACCIA, JB ;

ANDERSON, S ;

MCKEON, A ;

MCCARTHY, M ;

THOMAS, AB ;

VRIESENDORP, FJ ;

AUSTIN, SG ;

LINDSEY, JW ;

DIMACHKIE, M ;

CERRETA, E ;

KACHUCK, N ;

MCCARTHY, KA .

NEUROLOGY, 1995, 45 (07) :1268-1276

[10] Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis [J].

Mancardi, GL ;

Sardanelli, F ;

Parodi, RC ;

Melani, E ;

Capello, E ;

Inglese, M ;

Ferrari, A ;

Sormani, MP ;

Ottonello, C ;

Levrero, F ;

Uccelli, A ;

Bruzzi, P .

NEUROLOGY, 1998, 50 (04) :1127-1133

← 1 2 3 →